FibroBiologics, Inc.
FBLG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FBLG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications [sec_mda · as of 2024-11-12].
Key risk: Cash runway limited
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for FibroBiologics, Inc..
FibroBiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications [sec_mda · as of 2024-11-12].
- Clinical-stage biotechnology company focused on fibroblast-based therapies for chronic diseases with significant unmet medical needs [sec_mda · as of 2024-11-12].
- As of June 30, 2026, cash and equivalents were $3.5M, with a net loss of $4.1M and shareholders' equity of $6.2M [sec].
- Accumulated deficit was approximately $54.2 million as of December 31, 2025 [sec_mda · as of 2026-02-24].
- The company expects to continue incurring significant losses and will need substantial additional funding to support operations and growth strategy [sec_mda · as of 2026-02-24].
- Pipeline includes programs in wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and human longevity applications [sec_mda · as of 2024-11-12].
What works
- Focus on fibroblast-based therapies addresses a broad range of chronic diseases with high unmet medical need, potentially offering a differentiated platform [sec_mda · as of 2024-11-12].
- The company has multiple preclinical and clinical programs in development, which could provide multiple shots on goal for value creation [sec_mda · as of 2024-11-12].
What to weigh
- As of June 30, 2026, the company had only $3.5M in cash and equivalents, which may not be sufficient to fund operations for an extended period given ongoing losses [sec].
- Accumulated deficit of $54.2M as of December 31, 2025, with no current revenue from product sales, indicating a high cash burn rate [sec_mda · as of 2026-02-24].
- The company expects to need substantial additional funding and may have to relinquish valuable rights or accept unfavorable terms to secure capital [sec_mda · as of 2026-02-24].
- Development timelines and costs are highly uncertain, and the company may be forced to reduce or terminate operations if it fails to become profitable [sec_mda · as of 2026-02-24].
From the filings
Quoted directly from source documents.
The company is a clinical-stage biotechnology company focused on fibroblast-based therapies for chronic diseases.
“We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis (MS), degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications”
SEC MD&A · November 12, 2024
As of December 31, 2025, accumulated deficit was approximately $54.2 million.
“As of December 31, 2025, we had an accumulated deficit of approximately $54.2 million.”
SEC MD&A · February 24, 2026
The company may be forced to reduce or terminate operations if it fails to become profitable.
“If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.”
SEC MD&A · February 24, 2026
Risks & what to watch (4)›
Key risks
- Cash runway limited — Only $3.5M cash as of June 30, 2026, with ongoing net losses of $4.1M per quarter, suggesting a short cash runway [sec].
- No revenue from product sales — The company has no current revenue from product sales and expects to finance operations through equity or partnerships, which may dilute or restrict rights [sec_mda · as of 2026-02-24].
- Development uncertainty — Clinical trial timelines, costs, and outcomes are highly uncertain, and the company may need to raise additional capital to continue programs [sec_mda · as of 2026-02-24].
- Accumulated deficit — Accumulated deficit of $54.2M as of December 31, 2025, with no near-term path to profitability [sec_mda · as of 2026-02-24].
What to watch
- Cash runway and ability to raise additional funding, given $3.5M cash as of June 30, 2026 [sec].
- Progress of clinical trials for fibroblast-based therapies, especially in wound healing and multiple sclerosis [sec_mda · as of 2024-11-12].
- Any partnership, licensing, or strategic alliance announcements that could provide non-dilutive funding [sec_mda · as of 2026-02-24].
- Regulatory milestones such as IND acceptance or FDA feedback on clinical programs [sec_mda · as of 2026-02-24].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run FibroBiologics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FibroBiologics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.8 months
D/E 0.71 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$281K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 135,330 | $179K |
| geode capital management, llc | 29,609 | $39K |
| blackrock, inc. | 24,647 | $33K |
| renaissance technologies llc | 15,997 | $21K |
| vanguard fiduciary trust co | 6,380 | $8K |
| tower research capital llc (trc) | 460 | $607 |
| western wealth management, llc | 200 | $264 |
| islay capital management, llc | 169 | $223 |
| osaic holdings, inc. | 154 | $203 |
| bnp paribas financial markets | 66 | $87 |
Showing top 10 of 13 institutional holders of FibroBiologics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 2.4%
- Days to cover
- 0.1
- Shares short
- 99,974
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FBLG short interestGovernance
Frequently asked questions
What is the AI investment thesis for FibroBiologics, Inc.?
FibroBiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications [sec_mda · as of 2024-11-12].
Who is the CEO of FibroBiologics, Inc.?
Mr. Peter O'Heeron is the chief executive officer of FibroBiologics, Inc. (FBLG).
Where is FibroBiologics, Inc. headquartered?
FibroBiologics, Inc. (FBLG) is headquartered in Houston, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.